PARP Inhibitors Play Key Role in Prostate Cancer Paradigm, as Hunt for Biomarkers Continues
Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents
FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
August 26th 2021Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.
Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions
August 10th 2021The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.
Immunotherapy, Targeted Therapy, and Novel Strategies Progress Practice in GI Malignancies
August 9th 2021Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.